Graeme Poston
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Graeme Poston has a total of 133 co-authors. Here are the top co-authors by number of shared publications:
- Hassan Malik
Department of Hepatobiliary Surgery, University Hospitals Aintree, Liverpool, UK
11 shared publications Stephen Fenwick
Aintree University Hospital
9 shared publicationsDeclan Dunne
7 shared publicationsRobert Jones
4 shared publicationsMatthew Parry
3 shared publications- René Adam
Centre Hépato-Biliaire, Assistance Publique - Hôpitaux de Paris, Hôpital Universitaire Paul Brousse, Villejuif, France
3 shared publications
Latest Publications
- 1 June 2018
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 44 (6) , 771-777
The impact of primary tumour location in patients undergoing hepatic resection for colorectal liver metastasis
- 1 June 2018
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 44 (6) , 771-777
The impact of primary tumour location in patients undergoing hepatic resection for colorectal liver metastasis
- Open Access
- 8 January 2018
- Published by Springer Nature in BMC Cancer
- Vol. 18 (1) , 50
A modified TNM staging system for non-metastatic colorectal cancer based on nomogram analysis of SEER database
To revise the American Joint Committee on Cancer TNM staging system for colorectal cancer (CRC) based on a nomogram analysis of Surveillance, Epidemiology, and End Results (SEER) database, and to prove the rationality of enhancing T stage’s weighting in our previously proposed T-plus staging system. Total 115,377 non-metastatic CRC patients from SEER were randomly grouped as training and testing set by ratio 1:1. The Nomo-staging system was established via three nomograms based on 1-year, 2-year and 3-year disease specific survival (DSS) Logistic regression analysis of the training set. The predictive value of Nomo-staging system for the testing set was evaluated by concordance index (c-index), likelihood ratio (L.R.) and Akaike information criteria (AIC) for 1-year, 2-year, 3-year overall survival (OS) and DSS. Kaplan–Meier survival curve was used to valuate discrimination and gradient monotonicity. And an external validation was performed on database from the Second Affiliated Hospital of Zhejiang University (SAHZU). Patients with T1-2 N1 and T1N2a were classified into stage II while T4 N0 patients were classified into stage III in Nomo-staging system. Kaplan–Meier survival curves of OS and DSS in testing set showed Nomo-staging system performed better in discrimination and gradient monotonicity, and the external validation in SAHZU database also showed distinctly better discrimination. The Nomo-staging system showed higher value in L.R. and c-index, and lower value in AIC when predicting OS and DSS in testing set. The Nomo-staging system showed better performance in prognosis prediction and the weight of lymph nodes status in prognosis prediction should be cautiously reconsidered.
- 8 January 2018
- Published by Springer Nature in BMC Cancer
- Vol. 18 (1) , 50
Open AccessA modified TNM staging system for non-metastatic colorectal cancer based on nomogram analysis of SEER database
To revise the American Joint Committee on Cancer TNM staging system for colorectal cancer (CRC) based on a nomogram analysis of Surveillance, Epidemiology, and End Results (SEER) database, and to prove the rationality of enhancing T stage’s weighting in our previously proposed T-plus staging system. Total 115,377 non-metastatic CRC patients from SEER were randomly grouped as training and testing set by ratio 1:1. The Nomo-staging system was established via three nomograms based on 1-year, 2-year and 3-year disease specific survival (DSS) Logistic regression analysis of the training set. The predictive value of Nomo-staging system for the testing set was evaluated by concordance index (c-index), likelihood ratio (L.R.) and Akaike information criteria (AIC) for 1-year, 2-year, 3-year overall survival (OS) and DSS. Kaplan–Meier survival curve was used to valuate discrimination and gradient monotonicity. And an external validation was performed on database from the Second Affiliated Hospital of Zhejiang University (SAHZU). Patients with T1-2 N1 and T1N2a were classified into stage II while T4 N0 patients were classified into stage III in Nomo-staging system. Kaplan–Meier survival curves of OS and DSS in testing set showed Nomo-staging system performed better in discrimination and gradient monotonicity, and the external validation in SAHZU database also showed distinctly better discrimination. The Nomo-staging system showed higher value in L.R. and c-index, and lower value in AIC when predicting OS and DSS in testing set. The Nomo-staging system showed better performance in prognosis prediction and the weight of lymph nodes status in prognosis prediction should be cautiously reconsidered.
- 18 February 2017
- Published by Springer Nature in Current Treatment Options in Oncology
- Vol. 18 (2) , 8
Defining the Optimal Use of Ablation for Metastatic Colorectal Cancer to the Liver Without High-Level Evidence
The role of physical interventions (surgical resection and surgical/radiological ablation) for liver metastases of colorectal cancer has changed dramatically over the last 10–15 years. Whereas in the 1990s, when only those patients with up to three unilobar metastases were considered for any form of such intervention, our present approach to these physical interventions is determined by how much viable disease-free liver can be preserved (most authorities accepting 25–30% disease-free future remnant liver volume) and the possibility of further such interventions if the disease recurs in the liver. There is increasing evidence that for smaller tumours (<3 cm diameter), ablation therapy may be therapeutically the equivalent of surgical resection and possibly safer in high-risk patients with multiple comorbidities. Therefore, we now consider the use of such ablation therapies (with or without surgical resection) to be clinically effective when treating patients with multiple bilobar metastases that have shown good radiologic response to prior systemic therapy.
- 18 February 2017
- Published by Springer Nature in Current Treatment Options in Oncology
- Vol. 18 (2) , 8
Defining the Optimal Use of Ablation for Metastatic Colorectal Cancer to the Liver Without High-Level Evidence
The role of physical interventions (surgical resection and surgical/radiological ablation) for liver metastases of colorectal cancer has changed dramatically over the last 10–15 years. Whereas in the 1990s, when only those patients with up to three unilobar metastases were considered for any form of such intervention, our present approach to these physical interventions is determined by how much viable disease-free liver can be preserved (most authorities accepting 25–30% disease-free future remnant liver volume) and the possibility of further such interventions if the disease recurs in the liver. There is increasing evidence that for smaller tumours (<3 cm diameter), ablation therapy may be therapeutically the equivalent of surgical resection and possibly safer in high-risk patients with multiple comorbidities. Therefore, we now consider the use of such ablation therapies (with or without surgical resection) to be clinically effective when treating patients with multiple bilobar metastases that have shown good radiologic response to prior systemic therapy.
- 14 January 2017
- Published by Annual Reviews in Annual Review of Medicine
- Vol. 68 (1) , 183-196
Resection of Liver Metastases in Colorectal Cancer in the Era of Expanding Systemic Therapy
About 25% of patients with colorectal cancer develop liver metastases after resection of the primary tumor, and surgical resection of the metastases offers the only opportunity for long-term survival. However, only 20% of patients present with resectable disease. Deciding which patients should be offered surgery, and which should receive additional treatment in the form of perioperative chemotherapy, is complex. For the majority of patients who present with technically irresectable liver-limited disease, systemic downsizing chemotherapy offers the only opportunity to reach surgery and potential cure. Molecular analysis of tumor tissue is improving patient stratification, allowing more appropriate treatment selection, but is not yet a regular part of clinical practice. Decision making is limited by a lack of clear prospective evidence, and so multidisciplinary team assessment is essential to optimize outcomes.
- 14 January 2017
- Published by Annual Reviews in Annual Review of Medicine
- Vol. 68 (1) , 183-196
Resection of Liver Metastases in Colorectal Cancer in the Era of Expanding Systemic Therapy
About 25% of patients with colorectal cancer develop liver metastases after resection of the primary tumor, and surgical resection of the metastases offers the only opportunity for long-term survival. However, only 20% of patients present with resectable disease. Deciding which patients should be offered surgery, and which should receive additional treatment in the form of perioperative chemotherapy, is complex. For the majority of patients who present with technically irresectable liver-limited disease, systemic downsizing chemotherapy offers the only opportunity to reach surgery and potential cure. Molecular analysis of tumor tissue is improving patient stratification, allowing more appropriate treatment selection, but is not yet a regular part of clinical practice. Decision making is limited by a lack of clear prospective evidence, and so multidisciplinary team assessment is essential to optimize outcomes.
- 23 November 2016
- Published by Bioscientifica in Endocrine Abstracts
Prognostic factors that mandate long term follow up following surgery for appendix neuroendocrine tumours (aNETs)
Background: Appendiceal neuroendocrine tumours (aNETs) are usually diagnosed incidentally at appendicectomy, are indolent and rarely recur. Current ENETS guidelines inform aNETs management and highlight areas of uncertainty. We aimed to identify risk factors that predict lymph node metastasis, residual disease at completion surgery, or disease recurrence and also assessed survival according to ENETS stage. Methods: We retrospectively analysed a prospective database of patients diagnosed at our centre with aNETs from 1990 to 2016. We assessed risk factors for nodal metastases detected at primary or completion surgery, for residual disease at completion surgery, or for disease recurrence using logistic regression models. We assessed overall and aNET-specific survival using Kaplan-Meier analysis. Results: 93 patients (39 males, 54 females, median 47.9 (range 16.3–78.8) years) were included. Unsurprisingly, lymph node metastases significantly (P=0.0015) correlated with tumour size >2.0 cm. Residual disease was significantly predicted by tumour grade ≥G2 (P=0.0418) and goblet cell carcinoma (GCC) histology (P=0.0390). Disease recurrence was significantly predicted by GCC histology (P=0.0002). In the only recurrence where the primary aNET was non-GCC, the patient had undergone R1 resection of an ENETS stage 3a tumour 16 years earlier. Disease-specific 5 year survival for ENETS stages 1, 2a, 2b, 3a, 3b and 4 were 100, 100, 93, 100, 71, and 67% respectively. Overall 5 year survival mirrored these figures except for ENET stage 1 disease, where two non-NET related deaths occurred, hence survival of 92%. Significantly worse overall and disease-specific 5 year survivals occurred in ENETS stages 3b and 4 compared to others (P≤0.016). Conclusion: Tumour size >2.0 cm remains prognostic for lymph node metastasis. GCC histology was not only prognostic for recurrence after aNET resection, but, also prognostic for residual disease along with grade ≥G2. We suggest that extended follow-up (10 years or more) is appropriate for patients with ENETS stage disease (3b and 4), GCC histology, or following R1 resection because of their higher rates of disease recurrence and poorer overall survival.
- 23 November 2016
- Published by Bioscientifica in Endocrine Abstracts
Prognostic factors that mandate long term follow up following surgery for appendix neuroendocrine tumours (aNETs)
Background: Appendiceal neuroendocrine tumours (aNETs) are usually diagnosed incidentally at appendicectomy, are indolent and rarely recur. Current ENETS guidelines inform aNETs management and highlight areas of uncertainty. We aimed to identify risk factors that predict lymph node metastasis, residual disease at completion surgery, or disease recurrence and also assessed survival according to ENETS stage. Methods: We retrospectively analysed a prospective database of patients diagnosed at our centre with aNETs from 1990 to 2016. We assessed risk factors for nodal metastases detected at primary or completion surgery, for residual disease at completion surgery, or for disease recurrence using logistic regression models. We assessed overall and aNET-specific survival using Kaplan-Meier analysis. Results: 93 patients (39 males, 54 females, median 47.9 (range 16.3–78.8) years) were included. Unsurprisingly, lymph node metastases significantly (P=0.0015) correlated with tumour size >2.0 cm. Residual disease was significantly predicted by tumour grade ≥G2 (P=0.0418) and goblet cell carcinoma (GCC) histology (P=0.0390). Disease recurrence was significantly predicted by GCC histology (P=0.0002). In the only recurrence where the primary aNET was non-GCC, the patient had undergone R1 resection of an ENETS stage 3a tumour 16 years earlier. Disease-specific 5 year survival for ENETS stages 1, 2a, 2b, 3a, 3b and 4 were 100, 100, 93, 100, 71, and 67% respectively. Overall 5 year survival mirrored these figures except for ENET stage 1 disease, where two non-NET related deaths occurred, hence survival of 92%. Significantly worse overall and disease-specific 5 year survivals occurred in ENETS stages 3b and 4 compared to others (P≤0.016). Conclusion: Tumour size >2.0 cm remains prognostic for lymph node metastasis. GCC histology was not only prognostic for recurrence after aNET resection, but, also prognostic for residual disease along with grade ≥G2. We suggest that extended follow-up (10 years or more) is appropriate for patients with ENETS stage disease (3b and 4), GCC histology, or following R1 resection because of their higher rates of disease recurrence and poorer overall survival.
- 1 October 2016
- Published by AME Publishing Company in Translational Cancer Research
- Vol. 5 (S4) , S889-S891
Is there any role for liver resection in the treatment of liver metastases from gastric carcinoma?
Is there any role for liver resection in the treatment of liver metastases from gastric carcinoma?
- 1 October 2016
- Published by AME Publishing Company in Translational Cancer Research
- Vol. 5 (S4) , S889-S891
Is there any role for liver resection in the treatment of liver metastases from gastric carcinoma?
Is there any role for liver resection in the treatment of liver metastases from gastric carcinoma?
- 20 May 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (15_suppl) , 3526
Oncological benefit of parenchyma-preserving hepatectomy for colorectal liver metastasis.
3526 Background: Occasionally, major hepatectomy (MH), rather than parenchyma-preserving hepatectomy (PH), is performed for solitary colorectal liver metastasis (CLM). It is unclear whether PH has a disadvantage through increasing liver recurrence or provides an oncological benefit through increasing repeat hepatectomy. The aim of this study was to investigate the prognostic impact of PH vs. MH for solitary CLM. Methods: The study population consisted of a multicentric cohort of 16738 patients operated for CLM between January 2000 and June 2013, and whose data were collected in the LiverMetSurvey registry. Patients with a solitary CLM (≤ 50 mm in size) of the right liver were included in this study. The short- and long-term outcomes of the patients who performed PH (PH group) were compared to those who performed right hepatectomy (MH group). The PH group was matched to the MH group (1:1) by using a propensity score-based method. Results: Of 16738 patients consecutively resected for CLM, 2234 (13%) were eligible for the study, 1800 (11%) underwent PH, and 434 (2%) underwent right hepatectomy. In a matched cohort (PH group, n = 423, MH group, n = 423), PH group was associated with higher rates of liver recurrence (22% vs. 13%; p= 0.001), but PH group was associated with lower rates of extrahepatic disease recurrence (17% vs. 23%; p= 0.05). The 3- and 5-year overall survivals were similar (77% and 60% vs. 70% and 56%, respectively; p= 0.56). In the patients with liver-only recurrence (PH group, n = 284, MH group, n = 40) revealed that, repeat hepatectomy was more frequently performed in the PH group (67% vs. 41%; p= 0.04). The overall survivals at 3- and 5-year were significantly better in the PH group than in the MH group (76% and 60% vs. 65% and 33%, respectively; p= 0.04). Furthermore, the survivals after liver recurrence at 3- and 5-year were significantly better in the PH group than in the MH group (63% and 56% vs. 38% and 31%, respectively; p= 0.04). Conclusions: PH increased liver recurrence but more importantly improved overall survival in patients with liver-only recurrence through increasing repeat hepatectomy.PH should be considered as a standard procedure for solitary CLM.
- 20 May 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (15_suppl) , 3526
Oncological benefit of parenchyma-preserving hepatectomy for colorectal liver metastasis.
3526 Background: Occasionally, major hepatectomy (MH), rather than parenchyma-preserving hepatectomy (PH), is performed for solitary colorectal liver metastasis (CLM). It is unclear whether PH has a disadvantage through increasing liver recurrence or provides an oncological benefit through increasing repeat hepatectomy. The aim of this study was to investigate the prognostic impact of PH vs. MH for solitary CLM. Methods: The study population consisted of a multicentric cohort of 16738 patients operated for CLM between January 2000 and June 2013, and whose data were collected in the LiverMetSurvey registry. Patients with a solitary CLM (≤ 50 mm in size) of the right liver were included in this study. The short- and long-term outcomes of the patients who performed PH (PH group) were compared to those who performed right hepatectomy (MH group). The PH group was matched to the MH group (1:1) by using a propensity score-based method. Results: Of 16738 patients consecutively resected for CLM, 2234 (13%) were eligible for the study, 1800 (11%) underwent PH, and 434 (2%) underwent right hepatectomy. In a matched cohort (PH group, n = 423, MH group, n = 423), PH group was associated with higher rates of liver recurrence (22% vs. 13%; p= 0.001), but PH group was associated with lower rates of extrahepatic disease recurrence (17% vs. 23%; p= 0.05). The 3- and 5-year overall survivals were similar (77% and 60% vs. 70% and 56%, respectively; p= 0.56). In the patients with liver-only recurrence (PH group, n = 284, MH group, n = 40) revealed that, repeat hepatectomy was more frequently performed in the PH group (67% vs. 41%; p= 0.04). The overall survivals at 3- and 5-year were significantly better in the PH group than in the MH group (76% and 60% vs. 65% and 33%, respectively; p= 0.04). Furthermore, the survivals after liver recurrence at 3- and 5-year were significantly better in the PH group than in the MH group (63% and 56% vs. 38% and 31%, respectively; p= 0.04). Conclusions: PH increased liver recurrence but more importantly improved overall survival in patients with liver-only recurrence through increasing repeat hepatectomy.PH should be considered as a standard procedure for solitary CLM.
- 5 February 2016
- Published by Taylor & Francis in Colorectal Cancer
- Vol. 5 (1) , 5-8
Why I became a cancer surgeon
Graeme Poston speaks to Roshaine Gunawardana, Managing Commissioning Editor: Graeme Poston (DSc MB BS, MS, FRCS[Eng], FRCS[Ed]) is a consultant hepatobiliary surgeon at the University Hospital Aintree, Liverpool, UK and Professor of Surgery at the University of Liverpool. He enjoys an international reputation in hepatobiliary surgery. To date, he has personally performed over 900 major hepatobiliary resections. His unit at University Hospital Aintree is one of the largest tertiary resectional hepatobiliary practices in the UK, having performed over 2000 liver resections over the last 20 years. He gained his undergraduate medical training at St Georges Hospital Medical School, London, and postgraduate training at The Hammersmith Hospital and St Mary's Hospital, London and University of Texas Medical Branch, Galveston, TX, USA. He is a past-President of the European Society of Surgical Oncology, the Association of Upper Gastrointestinal Surgeons of Great Britain and Ireland, and the British Association of S...
- 5 February 2016
- Published by Taylor & Francis in Colorectal Cancer
- Vol. 5 (1) , 5-8
Why I became a cancer surgeon
Graeme Poston speaks to Roshaine Gunawardana, Managing Commissioning Editor: Graeme Poston (DSc MB BS, MS, FRCS[Eng], FRCS[Ed]) is a consultant hepatobiliary surgeon at the University Hospital Aintree, Liverpool, UK and Professor of Surgery at the University of Liverpool. He enjoys an international reputation in hepatobiliary surgery. To date, he has personally performed over 900 major hepatobiliary resections. His unit at University Hospital Aintree is one of the largest tertiary resectional hepatobiliary practices in the UK, having performed over 2000 liver resections over the last 20 years. He gained his undergraduate medical training at St Georges Hospital Medical School, London, and postgraduate training at The Hammersmith Hospital and St Mary's Hospital, London and University of Texas Medical Branch, Galveston, TX, USA. He is a past-President of the European Society of Surgical Oncology, the Association of Upper Gastrointestinal Surgeons of Great Britain and Ireland, and the British Association of S...
- 1 December 2015
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 41 (12) , 1559-1561
Global cancer surgery: The Lancet Oncology review
- 1 December 2015
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 41 (12) , 1559-1561
Global cancer surgery: The Lancet Oncology review
- Top Cited PapersOpen Access
- 1 November 2015
- Published by Elsevier in Cancer Treatment Reviews
- Vol. 41 (9) , 729-741
Managing synchronous liver metastases from colorectal cancer: A multidisciplinary international consensus
- 1 November 2015
- Published by Elsevier in Cancer Treatment Reviews
- Vol. 41 (9) , 729-741
Top Cited PapersOpen AccessManaging synchronous liver metastases from colorectal cancer: A multidisciplinary international consensus